These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31442252)

  • 21. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
    Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
    Joseph C; Alsaleem M; Orah N; Narasimha PL; Miligy IM; Kurozumi S; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jul; 182(2):267-282. PubMed ID: 32445177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
    Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
    PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors.
    Moazzezy N; Ebrahimi F; Sisakht MM; Yahyazadeh H; Bouzari S; Oloomi M
    Asian Pac J Cancer Prev; 2016; 17(1):249-54. PubMed ID: 26838218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
    Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
    JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study.
    Yamamura J; Kamigaki S; Tsujie M; Fujita J; Osato H; Higashi C; Kanaizumi H; Tanaka Y; Hamada M; Shinzaki W; Hashimoto Y; Komoike Y
    In Vivo; 2019; 33(1):281-287. PubMed ID: 30587637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
    Michaelidou K; Ardavanis A; Scorilas A
    Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
    Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
    Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
    Schiza A; Mauri D; Fredriksson I; Anna-Karin Wennstig ; Valachis A
    Breast Cancer Res Treat; 2021 Apr; 186(3):779-789. PubMed ID: 33258078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer.
    Kladi-Skandali A; Sideris DC; Scorilas A
    Clin Chem Lab Med; 2018 Dec; 57(2):276-287. PubMed ID: 30325729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
    Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
    Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of vacuole membrane protein 1 and its prognostic value in invasive ductal carcinoma of the breast].
    Liu F; Niu Y; Liu N; Zhang W; Wang SL; Liu H; Zhang TX
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):86-9. PubMed ID: 23710913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.